Hepatitis B

Rituximab Linked to HBV Reactivation in Patients With Prior Functional Cure

Rituximab Linked to HBV Reactivation in Patients With Prior Functional Cure

The study authors searched MEDLINE from inception through July 2018 to obtain relevant cohort studies and randomized trials assessing HBVr incidence secondary to pharmaceutical agents.

Patrons of 'Vampire Facial' Spa May Have Been Exposed to HIV

Patrons of 'Vampire Facial' Spa May Have Been Exposed to HIV

Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.

HBV Antibody Persistence in Adolescents Vaccinated With DTPa-HBV-IPV/Hib as Infants

HBV Antibody Persistence in Adolescents Vaccinated With DTPa-HBV-IPV/Hib as Infants

A robust anamnestic response was mounted in most adolescents when challenged with a dose of monovalent HBV vaccine.

Availability of Generic Antivirals for Hepatitis B Increasing

Availability of Generic Antivirals for Hepatitis B Increasing

Drop in median price of WHO-prequalified generic tenofovir from 208 to 32 from 2004 to 2016

Poor Adherence Contributes to Inadequate Uptake of Multidose Hepatitis Vaccine Schedules

Poor Adherence Contributes to Inadequate Uptake of Multidose Hepatitis Vaccine Schedules

By

Adherence and completion to multidose vaccine schedules for hepatitis A, B, and A-B are low, thereby rendering vaccination ineffective.

Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B

Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B

By

Patients with chronic hepatitis B have a lower risk of hepatic events if they achieve normal on-treatment ALT in the first 12 months of NA treatment.

HBV Infection May Not Be Associated With Increased Risk for Coronary Heart Disease

HBV Infection May Not Be Associated With Increased Risk for Coronary Heart Disease

Researchers conducted the first systematic review and meta-analysis to assess the relationship between HBV and the risk for coronary heart disease.

CDC: Recommendations on the Use of Heplisav-B Published

CDC: Recommendations on the Use of Heplisav-B Published

By

Benefits of protection with 2 doses administered over 1 month make the vaccine an important option for prevention of HBV.

Metabolic Syndrome Common With Chronic Hepatitis B Infection

Metabolic Syndrome Common With Chronic Hepatitis B Infection

Metabolic syndrome also associated with higher alanine aminotransferase levels longitudinally

End-of-Treatment HBsAg Levels May Predict HBV Relapse in Chronic Hepatitis B

End-of-Treatment HBsAg Levels May Predict HBV Relapse in Chronic Hepatitis B

End-of-treatment HBsAg levels may be a clinically useful biomarker to predict HBV relapse in patients with chronic hepatitis B regardless of HBeAg status.

BMI associated with hepatocellular carcinoma risk for patients with chronic hepatitis B virus

BMI associated with hepatocellular carcinoma risk for patients with chronic hepatitis B virus

BMI is positively correlated with increased hepatocellular carcinoma in patients with chronic HBV, though the risk is greater in women.

Maternal TDF not effective in reducing hepatitis B transmission

Maternal TDF not effective in reducing hepatitis B transmission

TDF did not reduce mother-to-child HBV transmission in mothers taking hepatitis B Ig and HBV vaccine.

Hepatitis B infection prevention: ACIP updated recommendations

Hepatitis B infection prevention: ACIP updated recommendations

By

The Work Group who authored the new recommendations was made up of professionals from academic medicine, federal and state public health agencies, and medical societies.

Over one-third of U.S. HIV patients are not vaccinated against hepatitis B

One third of HIV patients in the United States remain unvaccinated against hepatitis B.

FDA approves Heplisav-B vaccine for hepatitis B treatment

FDA approves Heplisav-B vaccine for hepatitis B treatment

By

The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.

Hepatitis increases mortality rates in HIV patients

Hepatitis increases mortality rates in HIV patients

By

Hepatitis B and hepatitis C may increase mortality risks in HIV patients.

Aspirin use associated with a reduced risk of HCC in hepatitis B patients

Aspirin use associated with a reduced risk of HCC in hepatitis B patients

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma.

AAP: Hepatitis B vaccine should be given within first 24 hours of life

AAP: Hepatitis B vaccine should be given within first 24 hours of life

The American Academy of Pediatrics recommends that the first dose of the hepatitis B vaccine should be given within the first 24 hours of life.

Telbivudine prevents hepatitis B transmission during early pregnancy

Telbivudine prevents hepatitis B transmission during early pregnancy

Telbivudine administered during early and middle pregnancy prevented hepatitis B transmission from mother to infants in all participants receiving antiviral treatment.

Blood-borne viruses more common in patients with severe mental illness

Blood-borne viruses more common in patients with severe mental illness

By

HIV, hepatitis B, and hepatitis C infections are more common among individuals with severe mental illness.

Hepatitis B vaccine reduces risk of non-Hodgkin lymphoma in adolescents

Hepatitis B vaccine reduces risk of non-Hodgkin lymphoma in adolescents

The universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents.

Tenofovir prevents prenatal transmission of HBV in pregnancy

Tenofovir prevents prenatal transmission of HBV in pregnancy

Pregnant women with a high hepatitis B viral load who receive tenofovir have a reduced risk for passing the virus to their child.

EASL releases updated guidelines for managing hepatitis B virus infection

EASL releases updated guidelines for managing hepatitis B virus infection

The updated guidelines include substantial changes in the management of hepatitis B based on the latest scientific evidence.

Statins may lower risk of cirrhosis decompensation in HBV and HCV

Statins may lower risk of cirrhosis decompensation in HBV and HCV

Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.

NASEM report aims to eliminate hepatitis B and C by 2030

NASEM report aims to eliminate hepatitis B and C by 2030

By

Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

By

The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.

Missed blood test results

Missed blood test results

By

A patient's positive hepatitis B results were overlooked for 7 years.

New hepatology rotation increases knowledge of liver disease among residents

New hepatology rotation increases knowledge of liver disease among residents

A new hepatology rotation increased the mean comfort level for managing several liver diseases.

Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritis

Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritis

The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares.

Sign Up for Free e-newsletters